Elusys is a private commercial-stage biopharmaceutical company that has achieved US, Canada, United Kingdom and European Union licensure for its lead antibody therapeutic, a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack.
ANTHIM® has been delivered to the US Strategic National Stockpile as the result of a successful, multi-year partnership with the US government.
Elusys has been awarded over $320 million in procurement and development contracts by the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Disease (NIAID) and the Department of Defense (DoD). Working closely with these agencies, Elusys has been able to advance ANTHIM to the commercial stage providing a therapeutic for inclusion in the Strategic National Stockpile to strengthen US biosecurity against a potential anthrax attack. ANTHIM was licensed for commercial use by the FDA in 2016. In addition to government contracts and grants, Elusys has received funding from a prestigious group of biotech investors, including Essex Woodlands Healthcare, Medimmune Ventures, Invesco Pfizer and Crescendo Ventures.
*SFL Pharmaceuticals Deutschland GmbH is the EU Marketing Authorization Holder
Elusys’ management team has decades of experience in the biopharmaceutical industry, which includes management of multiple US government contracts and deep experience in developing late-stage product candidates.
This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue
Mr. Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, where he spent 15 years managing pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, Mr. Eastman has helped build three private healthcare companies—Geron, HCORP, and Rinat NeuroscienceUnder his leadership, Geron became a cutting-edge biotech company which grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. At Rinat, a private biotech company spun out of Genentech with the support of Essex Woodlands in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006.
Mr. Eastman serves on the boards of Corium International, Elusys Therapeutics, Inc., IntegenX Inc., Open Monoclonal Technology, Inc. (“OMT”), and Revance Therapeutics, Inc.Mr. Eastman joined Essex Woodlands in the Palo Alto office in October 2006 and is a Managing Director.Mr. Eastman holds a Bachelor of Arts from Williams College and a Master of Business Administration degree from Columbia University.
Vera joined Elusys in 2005 as the Director of Finance and Controller and since October 2013, serves as the Vice President of Finance. Vera previously served as the CFO for the Global Network Engineering Group at AT&T. From 1993 to 2002, Vera served as the Controller for WorldPartners Company, a general partnership between AT&T, KDD, Singapore Telecom and Unisource NV which provided standardized telecommunication services to multinational companies. She is credited with establishing the end to end Finance organization at WorldPartners and contributed to its exponential growth in 3 years. Her prior responsibilities at AT&T included management positions in Internal Audit, Real Estate and Corporate Finance over a ten-year period. Vera holds an MBA in Accounting from Pace University and is a Certified Public Accountant in New York and New Jersey.
Jim has over 25 years of experience in commercial biopharmaceutical development and manufacturing. Prior to joining Elusys in 1999, he served as Director, Product Materials Development for Heska Corporation, a veterinary pharmaceutical company specializing in companion animal health. Previously, he served ten years with Genentech, Inc., in the Hybridoma Development Group as a Research Associate, where he gained extensive experience in the production and characterization of monoclonal antibodies. He developed assays and screening protocols that enabled the evaluation of molecules for AIDS therapeutics and the selection of monoclonal antibodies for allergy and cancer applications. Prior to Genentech, Jim worked at Syngene Products and Research, Inc., where he developed USDA licensed veterinary immunodiagnostics for feline and equine retroviral diseases. Jim received his Bachelor of Science degree in chemistry from the University of Florida and his Master of Science degree in biochemistry from the University of South Carolina.
Jerry brings more than 30 years of experience in corporate development strategic planning and operations to the company. Jerry joined Elusys in May 2007 and currently manages all corporate development activities. Prior to joining Elusys, Jerry was Vice President of Business Development at Valera Pharmaceuticals with responsibility for leading business development, strategic planning, and project management. Prior to Valera, he held position of increasing responsibility at Neose Technologies, Abbott Laboratories, BASF Pharma and Boots Pharmaceuticals. Jerry holds a Bachelor of Science degree in Applied Chemistry from DeMontfort University in England.
Robin brings over 30 years of US and global regulatory affairs experience to the company. Prior to joining Elusys, she held various positions with increasing responsibilities within Regulatory Affairs at Roche. Robin’s experience at Roche includes global filings and approvals for both drug and biologic products and spans multiple therapeutic areas. Most recently, she was Senior Director, US Regulatory Affairs, and Global Head, Regulatory Compliance and Standards at Roche. Robin’s regulatory career began at Enzon Pharmaceuticals, where she helped obtain approval for two orphan products. She holds a Bachelor of Arts degree in Biology from Susquehanna University and a Master’s of Science in Regulatory Affairs/Quality Assurance from Temple University.
Dr. Posillico has 30 years of experience in the biopharmaceutical industry and has held senior positions in general management, business development, marketing, and operations. She joined Elusys in 2002, as Vice President of Business Development and was promoted to Senior Vice President of Operations. In January 2005, she was named President and CEO. Prior to joining Elusys, she was Vice President of Business Development and Marketing at Physiome Sciences and Senior Vice President of Business Development at Apoptogen, Inc., a Canadian biotech company developing novel therapies for the treatment of apoptosis-related diseases. She also served on the management committee of the Canadian Medical Discovery Fund, an early-stage venture capital fund. Dr. Posillico spent eight years at Genzyme Corporation in several management positions, including Director of Sales and Marketing for ImmunoBiological Products and, ultimately served as General Manager and Senior Vice President in the Diagnostics Division.
She has served a term as Co-Chair of the Alliance for BioSecurity. Dr. Posillico also served as treasurer of the Board of Directors of BioNJ, the Biotechnology Council of New Jersey. Dr. Posillico received a Bachelor of Arts degree from the State University of New York at Potsdam and a PhD from Duke University.